{"name":"Taiho Pharmaceutical","slug":"taiho","ticker":"4578.T","exchange":"TSE (subsidiary of Otsuka Holdings)","domain":"taiho.co.jp","description":"Taiho Pharmaceutical Co., Ltd.  is a Japanese pharmaceutical company, and a subsidiary of Otsuka Holdings, which focuses on developing cancer treatments. Taiho, headquartered in Tokyo, Japan, is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.","hq":"Tokyo, Japan","founded":1946,"employees":"37758","ceo":"Teruhiro Utsugi, Ph.D.","sector":"Oncology / Specialty Pharma","stockPrice":11050,"stockChange":-145,"stockChangePercent":-1.3,"marketCap":"$5.8T","metrics":{"revenue":2468892114944,"revenueGrowth":8.4,"grossMargin":71.7,"rdSpend":0,"netIncome":363149983744,"cash":534645014528,"dividendYield":1.25,"peRatio":16.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"LONSURF patent cliff ($1.4B at risk)","drug":"LONSURF","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"TAS-102 patent cliff ($1.4B at risk)","drug":"TAS-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Cisplatin (arm B)","genericName":"Cisplatin (arm B)","slug":"cisplatin-arm-b","indication":"Metastatic testicular cancer","status":"phase_3"},{"name":"CPT-11, 5-FU and l-LV","genericName":"CPT-11, 5-FU and l-LV","slug":"cpt-11-5-fu-and-l-lv","indication":"Colorectal cancer","status":"phase_2"},{"name":"Gemcitabine plus TS-1","genericName":"Gemcitabine plus TS-1","slug":"gemcitabine-plus-ts-1","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Jeselhy","genericName":"Pimitespib","slug":"pimitespib","indication":"Gastrointestinal stromal tumor","status":"marketed"},{"name":"S-1 + Cisplatin (arm A)","genericName":"S-1 + Cisplatin (arm A)","slug":"s-1-cisplatin-arm-a","indication":"Gastric cancer","status":"phase_3"},{"name":"S-1 plus CDDP","genericName":"S-1 plus CDDP","slug":"s-1-plus-cddp","indication":"Gastric cancer","status":"phase_3"},{"name":"S-1 plus Cisplatin","genericName":"S-1 plus Cisplatin","slug":"s-1-plus-cisplatin","indication":"Advanced gastric cancer","status":"phase_3"},{"name":"TAS-118 plus Oxaliplatin","genericName":"TAS-118 plus Oxaliplatin","slug":"tas-118-plus-oxaliplatin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"TS-1 and cisplatin","genericName":"TS-1 and cisplatin","slug":"ts-1-and-cisplatin","indication":"Advanced gastric cancer","status":"phase_3"},{"name":"UFT (uracil, tegafur)","genericName":"UFT (uracil, tegafur)","slug":"uft-uracil-tegafur","indication":"Colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AB122","genericName":"AB122","slug":"ab122","indication":"Other","status":"phase_1"},{"name":"ASTX030","genericName":"ASTX030","slug":"astx030","indication":"Other","status":"phase_1"},{"name":"AB154","genericName":"AB154","slug":"ab154","indication":"Other","status":"phase_1"},{"name":"Placebo [Ambulatory Cohort] only","genericName":"Placebo [Ambulatory Cohort] only","slug":"placebo-ambulatory-cohort-only","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"AB122","genericName":"AB122","slug":"ab122","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASTX030","genericName":"ASTX030","slug":"astx030","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cisplatin (arm B)","genericName":"Cisplatin (arm B)","slug":"cisplatin-arm-b","phase":"phase_3","mechanism":"Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts and crosslinks, preventing DNA replication and triggering cancer cell death.","indications":["Metastatic testicular cancer","Metastatic ovarian cancer","Advanced bladder cancer","Head and neck cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"AB154","genericName":"AB154","slug":"ab154","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CPT-11, 5-FU and l-LV","genericName":"CPT-11, 5-FU and l-LV","slug":"cpt-11-5-fu-and-l-lv","phase":"phase_2","mechanism":"Topoisomerase I inhibitor","indications":["Colorectal cancer","Breast cancer"],"catalyst":""},{"name":"Gemcitabine plus TS-1","genericName":"Gemcitabine plus TS-1","slug":"gemcitabine-plus-ts-1","phase":"phase_3","mechanism":"Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells.","indications":["Pancreatic cancer","Gastric cancer","Biliary tract cancer"],"catalyst":""},{"name":"Jeselhy","genericName":"Pimitespib","slug":"pimitespib","phase":"marketed","mechanism":"Heat shock protein HSP 90-beta","indications":["Gastrointestinal stromal tumor"],"catalyst":""},{"name":"Placebo [Ambulatory Cohort] only","genericName":"Placebo [Ambulatory Cohort] only","slug":"placebo-ambulatory-cohort-only","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"S-1 + Cisplatin (arm A)","genericName":"S-1 + Cisplatin (arm A)","slug":"s-1-cisplatin-arm-a","phase":"phase_3","mechanism":"S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells.","indications":["Gastric cancer","Gastroesophageal junction cancer","Esophageal cancer"],"catalyst":""},{"name":"S-1 plus CDDP","genericName":"S-1 plus CDDP","slug":"s-1-plus-cddp","phase":"phase_3","mechanism":"S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation.","indications":["Gastric cancer","Gastroesophageal junction cancer","Esophageal cancer"],"catalyst":""},{"name":"S-1 plus Cisplatin","genericName":"S-1 plus Cisplatin","slug":"s-1-plus-cisplatin","phase":"phase_3","mechanism":"S-1 is a fluoropyrimidine derivative that inhibits thymidylate synthase, while cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription.","indications":["Advanced gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"TAS-118 plus Oxaliplatin","genericName":"TAS-118 plus Oxaliplatin","slug":"tas-118-plus-oxaliplatin","phase":"phase_3","mechanism":"TAS-118 is a thymidylate synthase inhibitor, and when combined with oxaliplatin, it targets rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"TS-1 and cisplatin","genericName":"TS-1 and cisplatin","slug":"ts-1-and-cisplatin","phase":"phase_3","mechanism":"TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription.","indications":["Advanced gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"UFT (uracil, tegafur)","genericName":"UFT (uracil, tegafur)","slug":"uft-uracil-tegafur","phase":"phase_3","mechanism":"UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death.","indications":["Colorectal cancer","Gastric cancer","Breast cancer"],"catalyst":""}],"recentEvents":[{"date":"2022-09-01","type":"regulatory","headline":"Taiho Pharmaceutical's LONSURF Receives Approval in Japan for Treatment of Gastric Cancer","summary":"LONSURF has been approved in Japan for the treatment of gastric cancer.","drugName":"LONSURF","sentiment":"positive"},{"date":"2020-03-31","type":"earnings","headline":"Taiho Pharmaceutical Reports Fiscal Year 2020 Earnings","summary":"Taiho Pharmaceutical reported its fiscal year 2020 earnings, with revenue of ¥143.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2019-12-20","type":"deal","headline":"Taiho Pharmaceutical Enters into Licensing Agreement with Merck KGaA for TAS-102","summary":"Taiho Pharmaceutical has entered into a licensing agreement with Merck KGaA for the development and commercialization of TAS-102 in the US and Canada.","drugName":"TAS-102","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"LONSURF","drugSlug":"trifluridine/tipiracil","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"TAS-102","drugSlug":"trifluridine/tipiracil","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":14,"phaseCounts":{"phase_1":3,"phase_3":9,"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Bristol-Myers Squibb","AstraZeneca"],"therapeuticFocus":["Oncology"],"financials":null,"yahoo":{"currentPrice":11050,"previousClose":11195,"fiftyTwoWeekHigh":11610,"fiftyTwoWeekLow":6465,"fiftyTwoWeekRange":"6465.0 - 11610.0","fiftyDayAverage":10313.76,"twoHundredDayAverage":8665.1,"beta":-0.08,"enterpriseValue":5672077885440,"forwardPE":21.3,"priceToBook":1.92,"priceToSales":2.36,"enterpriseToRevenue":2.3,"enterpriseToEbitda":9.62,"pegRatio":0,"ebitda":589933969408,"ebitdaMargin":23.9,"freeCashflow":191032754176,"operatingCashflow":403579011072,"totalDebt":227975004160,"debtToEquity":7.4,"currentRatio":2.17,"returnOnAssets":7.5,"returnOnEquity":12.5,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":11650,"targetHighPrice":15100,"targetLowPrice":10000,"dividendRate":140,"payoutRatio":0.2,"fiveYearAvgDividendYield":1.91,"exDividendDate":1782691200,"insiderHeldPercent":14.8,"institutionHeldPercent":32.6,"sharesOutstanding":527986249,"floatShares":441623451,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":685.13,"epsForward":519.18,"revenuePerShare":4657.41,"bookValue":5743.73,"officers":[{"age":67,"name":"Mr. Makoto  Inoue","title":"President, CEO & Representative Director"},{"age":64,"name":"Ms. Yuko  Makino","title":"CFO & Executive Director"},{"age":61,"name":"Ms. Noriko  Tojo","title":"Executive Director"},{"age":65,"name":"Mr. Yoshiro  Matsuo","title":"Executive Deputy President & Representative Director"},{"age":59,"name":"Mr. Masayuki  Kobayashi","title":"Executive Director"},{"age":59,"name":"Mr. Shuichi  Takagi","title":"Executive Director"},{"age":null,"name":"Tomohiro  Emura Ph.D.","title":"Executive VP & Operating Officer of IR, Public Relations, and Sustainability Promotion"},{"age":null,"name":"Chiaki  Sakurai","title":"Senior EVP, Operating Officer & Dir. of Nutraceutical Bus., Global Strat. and Planning Headquarters"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.otsuka.com/en/ir/","website":"https://www.otsuka.com","phone":""}}